ASCO 2015

Area: Oncology

Location: Chicago, United States

Date: May 29 to June 2

Description:

American Society of Clinical Oncology


Search in Scientific Content:
Date
Filters:
Phase I/II
5:57

Phase I/II safety and antitumor activity of nivolumab in patients with advanced HCC

Presenter: Anthony B. El-Khoueiry
Oncology
ntitumor a
6:34

ntitumor activity and safety of pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (KEYNOTE-012)

Presenter: Tanguy Seiwert
Oncology
Phase III,
8:35

Phase III, randomized trial (CheckMate 057) of nivolumab vs. docetaxel in advanced non-squamous cell NSCLC

Presenter: Luis Paz-Ares
Oncology
PD-1 Block
5:13

PD-1 Blockade in Tumors with Mismatch Repair Deficiency

Presenter: Dung T. Le
Oncology
SIRIUS, a ...
3:08

SIRIUS, a phase II study of daratumumab monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma

Presenter: Saad Z. Usmani
Oncology
Ibrutinib
7:14

Ibrutinib combined with bendamustine and rituximab in previously treated CLL/SLL

Presenter: Asher Chanan-Khan
Oncology
GADOLIN: a
7:50

GADOLIN: a phase III study of obinutuzumab plus bendamustine vs. bendamustine in rituximab-refractory non-Hodgkin lymphoma

Presenter: Laurie Helen Sehn
Oncology
PERSIST-1
6:34

PERSIST-1 phase III study of pacritinib vs. best available therapy in myelofibrosis

Presenter: Ruben A. Mesa
Oncology
A phase II
3:51

A phase III protocol of docetaxel and prednisone, the first effective adjuvant chemotherapy for high-risk, localized prostate cancer

Presenter: Howard M. Sandler
Oncology
Extensive
3:28

Extensive lymph node surgery may not be necessary for all melanoma patients

Presenter: Claus Garbe
Oncology
Randomized
3:07

Randomized, open-label, multicenter, phase III study of eribulin vs. dacarbazine in leiomyosarcoma and adipocytic sarcoma

Presenter: Patrick Schoeffski
Oncology
Anastrazol
4:23

Anastrazole offers higher breast cancer-fee survival rates than tamoxifen following DCIS in postmenopausal patients

Presenter: Richard G. Margolese
Oncology
PALOMA3: a
3:50

PALOMA3: a double-blind, phase III trial of palbociclib in HR+, HER2- metastatic breast cancer that progressed on endocrine therapy

Presenter: Nicholas C. Turner
Oncology
Reduction
4:39

Reduction in late mortality among 5-year survivors of childhood cancer

Presenter: Gregory T. Armstrong
Oncology
Elective v
4:18

Elective vs. therapeutic neck dissection in the clinically node negative early oral cancera

Presenter: Anil D’Cruz
Oncology

Phase III randomized trial of whole brain radiation therapy in addition to radiosurgery in patients with 1 to 3 brain metastases

Presenter: Jan C. Buckner
Oncology
US on firs
6:31

US on first data with nivolumab in patients with advanced HCC

Presenter: Anthony B. El-Khoueiry
Oncology
Illuminati
4:51

Illumination and Innovation: Transforming Data into Learning

Presenter: Peter Paul Yu
Oncology
Expert on
7:19

Expert on novelties of immunotherapy at ASCO2015

Presenter: Gregory A. Masters
Oncology
Mismatch r
4:03

Mismatch repair deficiency predicts pembrolizumab response in colorectal cancer

Presenter: Luis A. Diaz Jr.
Oncology
Pembrolizu
4:41

Pembrolizumab in patients with advanced squamous cell carcinoma of the head & neck

Presenter: Tanguy Seiwert
Oncology
CheckMate
5:04

CheckMate 057 trial of nivolumab vs. docetaxel in advanced non-squamous cell NSCLC

Presenter: Luis Paz-Ares
Oncology
Scientific
10:31

Scientific novelties of ASCO2015

Presenter: Alan Venook
Oncology
PERSIST-1
4:04

PERSIST-1 study of pacritinib versus best available therapy in myelofibrosis

Presenter: Ruben A. Mesa
Oncology
GADOLIN: a
4:54

GADOLIN: a phase III study of obinutuzumab in rituximab-refractory non-Hodgkin lymphoma

Presenter: Laurie Helen Sehn
Oncology
Bruton’s t
6:54

Bruton’s tyrosine kinase ibrutinib in previously treated CLL/SLL

Presenter: Asher Chanan-Khan
Oncology
Eribulin e
4:07

Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

Presenter: Patrick Schoeffski
Oncology
Novel targ
3:34

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer (PALOMA3 study)

Presenter: Nicholas C. Turner
Oncology
CheckMate ...
5:58

CheckMate 067: Phase III trial of nivolumab ± ipilimumab vs. ipilimumab alone in treatment-naive patients with advanced melanoma

Presenter: Jedd Wolchok
Oncology
ASCO2015 m
8:15

ASCO2015 melanoma trial results

Presenter: Steven O'Day
Oncology
ASCO2015 w
19:46

ASCO2015 with the eye of a melanoma expert

Presenter: Jeffrey Weber
Oncology
ASCO2015 n
5:57

ASCO2015 novelties in treatment of prostate cancer

Presenter: Oliver Sartor
Oncology

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASCO 2017

2017-06-02 - 2017-06-06
Chicago, United States

SABCS 2016

2016-12-06 - 2016-12-10
San Antonio, United States

ESMO 2016

2016-10-07 - 2016-10-11
Copenhagen, Denmark

ASCO 2016

2016-06-03 - 2016-06-07
Chicago, United States

ELCC 2016

2016-04-13 - 2016-04-16
Geneva, Switzerland

ESMO ECCO 2015

2015-09-25 - 2015-09-29
Vienna, Austria

ELCC 2015

2015-04-15 - 2015-04-18
Geneva, Switzerland

Bratislava 2014

2014-10-09 - 2014-10-10
Bratislava, Slovakia